{
    "2021-03-31": [
        [
            {
                "time": "2023-04-01",
                "original_text": "原则上不拓展新赛道、仍将布局白酒复星业绩发布会还有哪些看点",
                "features": {
                    "keywords": [
                        "白酒",
                        "复星",
                        "业绩发布"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "消费品",
                        "白酒"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-04-01",
                "original_text": "瑞信：下调复星医药目标价至44港元 评级跑赢大市 机构下调估值",
                "features": {
                    "keywords": [
                        "瑞信",
                        "复星医药",
                        "目标价",
                        "下调"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-04-01",
                "original_text": "人均亏1.2万，一季度A股领跌全球",
                "features": {
                    "keywords": [
                        "A股",
                        "领跌",
                        "全球"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "市场整体"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-04-01",
                "original_text": "复星医药吴以芳：器械与诊断业务增长可期 不断推进ESG管理",
                "features": {
                    "keywords": [
                        "复星医药",
                        "器械",
                        "诊断",
                        "ESG"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "器械",
                        "诊断"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-04-01",
                "original_text": "最新！31家药企高管离职（附名单） 董监高成员变化",
                "features": {
                    "keywords": [
                        "药企",
                        "高管离职",
                        "董监高"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-04-01",
                "original_text": "复星国际董事长：推进疫苗国内上市，继续坚持全球化",
                "features": {
                    "keywords": [
                        "复星国际",
                        "疫苗",
                        "全球化"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-04-01",
                "original_text": "创新成果加速转化落地 复星医药业绩将持续稳定增长",
                "features": {
                    "keywords": [
                        "创新",
                        "复星医药",
                        "增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-04-01",
                "original_text": "里昂：复星医药目标价升89%至43.56港元 升至买入评级",
                "features": {
                    "keywords": [
                        "里昂",
                        "复星医药",
                        "目标价",
                        "上调"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-04-01",
                "original_text": "华东医药引进的叶酸受体α靶向ADC获批临床丨医麦猛爆料",
                "features": {
                    "keywords": [
                        "华东医药",
                        "叶酸受体",
                        "ADC",
                        "临床"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物技术"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-04-01",
                "original_text": "复星国际(00656-HK)郭广昌:选择疫苗研发技术以国家利益为先",
                "features": {
                    "keywords": [
                        "复星国际",
                        "郭广昌",
                        "疫苗",
                        "国家利益"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}